Expertise in
22
conditions

Dr. Matthew D. Cheney

Radiation Oncology
Spectrum Healthcare Partners, P.A.
333 Borthwick Ave, 
Portsmouth, NH 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
22
conditions
Spectrum Healthcare Partners, P.A.
333 Borthwick Ave, 
Portsmouth, NH 

Overview

Matthew Cheney is a Radiation Oncologist practicing medicine in Portsmouth, New Hampshire.

Dr. Cheney is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Laryngeal Cancer, Lung Cancer, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 22 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in ME

Hospital Affiliations

Lincolnhealth
Mainehealth Mid Coast Hospital
Mainehealth Maine Medical Center
Mainehealth Pen Bay Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Spectrum Healthcare Partners, P.A.
333 Borthwick Ave, Portsmouth, NH 03801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Apalutamide, Goserelin acetate, Leuprolide acetate
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Other, Procedure, Biological, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed
Study Phase: Phase 2/Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

6 Total Publications

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: August 08, 2024
Similar Doctors
Expertise in
20
conditions
Dr. Brian M. Alexander
Radiation Oncology
Expertise in
20
conditions
Dr. Brian M. Alexander
Radiation Oncology
Referral may be required

Brigham And Women's Hospital

75 Francis St, 
Boston, MA 
 (52.9 miles away)
617-732-6313
Languages Spoken:
English
See accepted insurances

Brian Alexander is a Radiation Oncologist practicing medicine in Boston, Massachusetts. Dr. Alexander is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Brain Tumor, Glioma, and Tissue Biopsy.

Expertise in
26
conditions
Dr. Helen Shih
Radiation Oncology
Expertise in
26
conditions
Dr. Helen Shih
Radiation Oncology
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (50.5 miles away)
617-724-9627
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Helen Shih is a Radiation Oncologist practicing medicine in Boston, Massachusetts. Dr. Shih is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Meningioma, Brain Tumor, Astrocytoma, Posterior Fossa Tumor, and Tissue Biopsy. Dr. Shih is currently accepting new patients.

Expertise in
13
conditions
Dr. Jennifer Y. Wo
Radiation Oncology
Expertise in
13
conditions
Dr. Jennifer Y. Wo
Radiation Oncology
Referral may be required

Office

100 Blossom St, 
Boston, MA 
 (50.4 miles away)
617-726-6050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Wo is a Radiation Oncologist practicing medicine in Boston, Massachusetts. Dr. Wo is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Anal Cancer, Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Wo is currently accepting new patients.

Frequently Asked Questions about Dr. Matthew D. Cheney

Is Dr. Matthew D. Cheney a top-rated expert for Familial Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew D. Cheney is classified as an Distinguished expert for Familial Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew D. Cheney specialize in?

While Dr. Matthew D. Cheney is a Radiation Oncology, they have specific expertise in Familial Prostate Cancer, Prostate Cancer, and Laryngeal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Matthew D. Cheney participate in research or clinical trials?

Yes. Dr. Matthew D. Cheney has published 6 articles and abstracts on conditions like Familial Prostate Cancer. You can view a list of Dr. Matthew D. Cheney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew D. Cheney accept my insurance?

Dr. Matthew D. Cheney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cheney's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile